Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linn Reinholdt"'
Autor:
Ditte Starberg Jespersen, Julie Støve Bødker, Steffen Falgreen, Suzette Sørensen, Hans Erik Johnsen, Maria Bach Laursen, Martin Bøgsted, Karen Dybkær, Anna Amanda Schönherz, Linn Reinholdt, Hanne Due, Marianne Schmidt Ettrup, Rasmus Røge, Alexander Schmitz, Lykke Christina Grubach
Publikováno v:
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ', Oncotarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understoo
Autor:
Steffen Falgreen, Maria Bach Laursen, Rasmus Froberg Brøndum, Linn Reinholdt, Alexander Schmitz, Anna Amanda Schönherz, Martin Bøgsted, Karen Dybkær, Hanne Due, Marianne Tang Severinsen, Mette Nyegaard, Hans Erik Johnsen, Lasse Hjort Jakobsen, Tarec Christoffer El-Galaly, Julie Støve Bødker
Publikováno v:
Bødker, J S, Severinsen, M T, El-Galaly, T C, Brøndum, R F, Laursen, M B, Larsen, S F, Nyegaard, M, Schmitz, A, Jakobsen, L H, Schönherz, A A, Due, H, Reinholdt, L, Bøgsted, M, Dybkær, K & Johnsen, H E 2017, ' Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission ', Experimental Hematology & Oncology, vol. 6, 3 . https://doi.org/10.1186/s40164-016-0063-0
Experimental Hematology & Oncology
Experimental Hematology & Oncology
Background The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing and global gene expression in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02807553a40a8bb1558878e8bda14af5
https://vbn.aau.dk/da/publications/c11d8826-a5a8-4d0c-abc4-a0965e879bd3
https://vbn.aau.dk/da/publications/c11d8826-a5a8-4d0c-abc4-a0965e879bd3
Autor:
Martin Boegsted, Hans Erik Johnsen, Steffen Falgreen, Maria Bach Laursen, Linn Reinholdt, Julie Støve Bødker, Karen Dybkær, Alexander Schmitz
Publikováno v:
Reinholdt, L R, Laursen, M B, Larsen, S F, Schmitz, A, Bødker, J S, Bøgsted, M, Johnsen, H E & Dybkær, K 2015, ' High Expression of CXCR4 Impairs Anti-CD20 Monoclonal Antibody (Rituximab)-Dependent Cytotoxicity in Diffuse Large B-Cell Lymphoma ', Blood, vol. 126, no. 23, pp. 1455 . < http://www.bloodjournal.org/content/126/23/1455.full.pdf >
Aalborg University
Aalborg University
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell-derived non-Hodgkin lymphoma, with a varying response and long-term outcome following therapy. The anti-CD20 monoclonal antibody rituximab has improved the survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d306174ddfc1cc53cbad3cb3e3ace437
https://vbn.aau.dk/da/publications/d18883b2-6534-45b3-a00b-e771c4c048db
https://vbn.aau.dk/da/publications/d18883b2-6534-45b3-a00b-e771c4c048db
Autor:
Karen Dybkær, Hans Erik Johnsen, Linn Reinholdt, Alexander Schmitz, Martin Bøgsted, Maria Bach Laursen, Julie Støve Bødker, Lasse Hjort Jakobsen
Publikováno v:
Biomarker Research
Reinholdt, L, Laursen, M B, Schmitz, A, Bødker, J S, Jakobsen, L H, Bøgsted, M, Johnsen, H E & Dybkær, K 2016, ' The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines ', Biomarker Research, vol. 4, 12 . https://doi.org/10.1186/s40364-016-0067-2
Reinholdt, L, Laursen, M B, Schmitz, A, Bødker, J S, Jakobsen, L H, Bøgsted, M, Johnsen, H E & Dybkær, K 2016, ' The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines ', Biomarker Research, vol. 4, 12 . https://doi.org/10.1186/s40364-016-0067-2
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with variable clinical outcome, accounting for at least 25-30 % of adult non-Hodgkin lymphomas. Approximately one third of DLBCL patients are not cured by the currently used tr